QED Therapeutics Stock
A biotechnology company focused on precision medicine for FGFR-driven disorders.
About QED Therapeutics Stock
QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Their lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. They plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.
Funding History
| January 2018 | $65.0M |
|---|
Management
President
Neil Kumar
CRO
Curtis Scribner
Other Companies
EquityZen does not have an affiliation with, formal relationship with, or endorsement from QED Therapeutics or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
